Skip to Content

Bupivacaine liposome Pregnancy and Breastfeeding Warnings

Bupivacaine liposome is also known as: Exparel

Medically reviewed on April 23, 2018

Bupivacaine liposome Pregnancy Warnings

Animal studies have revealed embryofetal death and decreased pup survival. There are no controlled data in human pregnancy.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

Use is not recommended.

US FDA pregnancy category: Not assigned.

Risk Summary: Advise pregnant women of the potential risks to a fetus.

See references

Bupivacaine liposome Breastfeeding Warnings

Benefit should outweigh risk.

Excreted into human milk: Yes (in small amounts)

Comments: This drug has been used without apparent harmful effects in the nursing infant.

See references

References for pregnancy information

  1. "Product Information. Exparel (bupivacaine liposome)." Pacira Pharmaceuticals Inc, San Diego, CA.

References for breastfeeding information

  1. "Product Information. Exparel (bupivacaine liposome)." Pacira Pharmaceuticals Inc, San Diego, CA.
  2. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT." ([cited 2013 -]):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide